Catalyst Pharmaceuticals (CPRX) Current Assets (2010 - 2026)

Catalyst Pharmaceuticals has reported Current Assets for 17 years, with the latest figure at $940.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 37.14% year-over-year to $940.4 million; the trailing twelve-month figure through Mar 2026 stood at $940.4 million (up 37.14% YoY), and the FY2025 full-year result was $894.0 million, up 43.36% from the prior year.
• Current Assets for Q1 2026 stood at $940.4 million, up from $894.0 million in the prior quarter.
• The five-year high for Current Assets was $940.4 million in Q1 2026, with the low at $192.0 million in Q3 2023.
• Historically, Current Assets has averaged $475.6 million across 5 years, with a median of $404.6 million in 2024.
• Annual changes were most pronounced in 2023 — Current Assets tumbled 31.63% — and 2024, when it jumped 184.33%.
• Catalyst Pharmaceuticals' Current Assets stood at $320.8 million in 2022, then sank by 31.63% to $219.3 million in 2023, then jumped by 184.33% to $623.6 million in 2024, then surged by 43.36% to $894.0 million in 2025, then climbed by 5.19% to $940.4 million in 2026.
• The last three Current Assets figures came in at $940.4 million (Q1 2026), $894.0 million (Q4 2025), and $852.5 million (Q3 2025), per Business Quant data.